# CRDL catalysts: Cardiol Therapeutics Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/crdl/catalysts

> Cardiol Therapeutics Inc. (CRDL) has 1 upcoming catalyst. The next is the CRD-38 topline data readout, mid-2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for CRDL?

Cardiol Therapeutics Inc. (CRDL) has 1 upcoming catalyst. The next is the CRD-38 topline data readout, mid-2027. Press release filed with the SEC (EX-99): "Topline results are anticipated in mid-2027, following completion of expanded enrollment and the required patient follow-up." [Calendar and source filings](https://sec-api.dev/companies/crdl/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-126269, https://www.sec.gov/Archives/edgar/data/1702123/000110465926126269/tm2629596d1_ex99-2.htm (retrieved 2026-11-12). Last confirmed 2026-11-12. Cite: https://sec-api.dev/companies/crdl/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Cardiol Therapeutics Inc. |
| Ticker | CRDL (Nasdaq) |
| SEC CIK | 1702123 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/crdl |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2024 | [CardiolRx™ (cardiolrx) topline data readout](https://sec-api.dev/pdufa/cardiolrx) | CRDL |  | completed, positive | "(vi) In June 2024, the Corporation reported positive topline 8-week clinical data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1702123/000110465924119139/tm2423889d1_ex99-2.htm)) |
| Jun 2024 | [Cardiol Therapeutics Inc. topline data readout](https://sec-api.dev/companies/crdl/catalysts) | CRDL |  | completed, positive | "In June 2024, the Corporation reported positive topline 8-week clinical data from its MAvERIC-Pilot study." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1702123/000110465924119139/tm2423889d1_ex99-2.htm)) |
| Jun 2024 | [CRD-38 topline data readout](https://sec-api.dev/pdufa/crd-38) | CRDL |  | completed, positive | "In June 2024, the Corporation reported positive topline 8-week clinical data from its MAvERIC-Phase II study and in November 2024, the Corporation reported comprehensive MAvERIC-Phase" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1702123/000110465926094885/tm2622666d1_ex99-2.htm)) |
| Q1 2025 | [Cardiol Therapeutics Inc. topline data readout](https://sec-api.dev/companies/crdl/catalysts) | CRDL |  | delayed | "The Corporation expects to report topline data in Q1 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1702123/000110465924119139/tm2423889d1_ex99-2.htm)) |
| Q2 2025 | [CardiolRx™ (cardiolrx) topline data readout](https://sec-api.dev/pdufa/cardiolrx) | CRDL | acute myocarditis, with topline data | scheduled | "Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patients with acute myocarditis, with topline data expected in Q2 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1702123/000106299325006610/exhibit99-1.htm)) |
| Sep to Dec 2026 | [CardiolRx™ (cardiolrx) topline data readout](https://sec-api.dev/pdufa/cardiolrx) | CRDL | Recurrent Pericarditis | scheduled | "NCT06708299 (CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-09-21 (ESTIMATED); Lead Sponsor Cardiol Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06708299)) |
| September 2026 | [CardiolRx™ (cardiolrx) primary completion](https://sec-api.dev/pdufa/cardiolrx) | CRDL | Recurrent Pericarditis | delayed | "NCT06708299 (CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-09-21 (ESTIMATED); Lead Sponsor Cardiol Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06708299)) |
| mid-2027 | [CRD-38 topline data readout](https://sec-api.dev/pdufa/crd-38) | CRDL |  | scheduled | "Topline results are anticipated in mid-2027, following completion of expanded enrollment and the required patient follow-up." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1702123/000110465926126269/tm2629596d1_ex99-2.htm)) |

## Drugs

- [CardiolRx™ (cardiolrx)](https://sec-api.dev/pdufa/cardiolrx): acute myocarditis, with topline data, Recurrent Pericarditis
- [CRD-38](https://sec-api.dev/pdufa/crd-38): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/crdl/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CRDL catalysts: Cardiol Therapeutics Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/crdl/catalysts

```bibtex
@misc{secapidev_companies_crdl_catalysts_20261116,
  title        = {CRDL catalysts: Cardiol Therapeutics Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/crdl/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_crdl_catalysts_20261116","title":"CRDL catalysts: Cardiol Therapeutics Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/crdl/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
